In summary, we proved that CLEC5A expression is associated with immune infiltration and affects immunotherapy sensitivity patient’s prognosis in pan-cancer, suggesting that CLEC5A can serve as a biomarker for tumor immunity and prognosis of a potential promising anti-tumor therapeutic target. The gene discussed is CLEC5A; the disease is neoplasm.